Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalCCEL +3.93%58 EV-to-EBITDA is 47.76 as of Aug. 05, 2026, which is 390% above its 10-year median of 9.75. GuruFocus rates CCEL with a GF Score™ of 58/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 90.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cryo-Cell International's enterprise value is $35.63 Mil.
Cryo-Cell International's EBITDA for the trailing twelve months (TTM) ended in May. 2026 was $0.75 Mil. Therefore, Cryo-Cell International's EV-to-EBITDA for today is 47.76.
The historical rank and industry rank for Cryo-Cell International's EV-to-EBITDA or its related term are showing as below:
CCEL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.45 Med: 9.75 Max: 61.99
Current: 47.76
During the past 13 years, the highest EV-to-EBITDA of Cryo-Cell International was 61.99. The lowest was -161.45. And the median was 9.75.
CCEL's EV-to-EBITDA is ranked worse than 90.55% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.015
vs CCEL: 47.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cryo-Cell International (AMEX:CCEL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryo-Cell International's PE Ratio (TTM) for today is calculated as:
Cryo-Cell International's share price for today is $3.70.
Cryo-Cell International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Cryo-Cell International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's EV-to-EBITDA falls into.
Cryo-Cell International's current Enterprise Value is $35.63 Mil.
Cryo-Cell International's EBITDA for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (CCEL) has a EV-to-EBITDA of 47.76 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cryo-Cell International. This is 390% above median its historical median of 9.75. According to the industry distribution chart, Cryo-Cell International ranks #460 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 90.6%.
Is Cryo-Cell International's EV-to-EBITDA too high?
Cryo-Cell International's current EV-to-EBITDA of 47.76 is 390% above median its 10-year median of 9.75. The Healthcare Providers & Services industry median EV-to-EBITDA is 11.02. Cryo-Cell International's value of 47.76 is 333.6% above this industry median. Based on the distribution chart, Cryo-Cell International ranks #460 out of 508 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's EV-to-EBITDA compare to EHSI and PIII?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #460 out of 508 companies for EV-to-EBITDA. This places Cryo-Cell International in the lower half of its industry. The industry median EV-to-EBITDA is 11.02. Cryo-Cell International's value of 47.76 is 333.6% above this benchmark. While the company's 10-year median is 9.75 vs. the industry median of 11.02, Cryo-Cell International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.02, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current EV-to-EBITDA of 47.76 is 333.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cryo-Cell International. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current EV-to-EBITDA is 47.76, which is 390% above median its own 10-year median of 9.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.70 — trading 32.1% below its estimated fair value. The current EV-to-EBITDA is 47.76, which is 390% above median its 10-year median of 9.75 and 333.6% above the Healthcare Providers & Services industry median of 11.02. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current EV-to-EBITDA is 47.76 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (CCEL) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of $3.70 is trading 32.1% below its estimated GF Value™ of $5.45.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for CCEL:
EV-to-EBITDA: 47.76 (390% above median its 10-year median of 9.75)
GF Value™: $5.45 vs. price of $3.70 (32.1% below fair value)
Industry Position: 333.6% above the Healthcare Providers & Services median (#460 of 508)
No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for CCEL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CCEL has been successfully added to your 
